WO2002059091A1 - Procede de preparation de derives d'acide cyanophenylbenzoique - Google Patents
Procede de preparation de derives d'acide cyanophenylbenzoique Download PDFInfo
- Publication number
- WO2002059091A1 WO2002059091A1 PCT/JP2002/000437 JP0200437W WO02059091A1 WO 2002059091 A1 WO2002059091 A1 WO 2002059091A1 JP 0200437 W JP0200437 W JP 0200437W WO 02059091 A1 WO02059091 A1 WO 02059091A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- methyl
- following formula
- cyanophenyl
- acid derivative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
Definitions
- the present invention provides a compound of formula (IV)
- the present invention relates to a method for producing 3- (3-cyanofur) -15-( ⁇ [(4-pyridyl) methyl] amino ⁇ methyl) benzoic acid derivative represented by (IV) or a salt thereof.
- 3- (3-cyanophen) -1 5-( ⁇ ) is useful as an intermediate for the production of a novel selective activated blood coagulation factor X (hereinafter abbreviated as FXa) inhibitor.
- FXa novel selective activated blood coagulation factor X
- antithrombin agents have been developed as thrombostatic agents, but these antithrombin agents have a tendency to bleed because they inhibit the anticoagulant effect as well as the thrombin aggregation of platelets by thrombin. It is known that there is a danger that coagulation ability cannot be easily controlled. Therefore, an anticoagulant based on a mechanism of action other than the thrombin inhibitory action was developed, and among them, an anticoagulant having an excellent FXa inhibitory action was described in International Patent Publication WO099 / 26918. The biphenylamidine derivative of ⁇ has been found.
- the production intermediate 3- (3-cyanofur) -1 5 -( ⁇ [(1_tert-butoxycarbonyl 4-piperidyl) methyl] amino ⁇ methyl) benzoic acid derivative is 3- (3-cyanofuryl) -15- (hydroxymethyl) benzoic acid derivative
- the hydroxymethyl group is brominated with linolebromide in getyl ether to convert it to the corresponding bromomethyl group, which is then converted to 41-aminomethyl-11- (tert-butoxycarbonyl) piperidine.
- the 4-aminomethyl-1- (tert-butoxycarbonyl) piperidine used here is obtained by reacting 4_aminomethylbiperidine with benzaldehyde once to immobilize the primary amino group. After protection, the secondary amino group of the piperidine ring must be tert-butoxycarponylated, and finally, it must be preliminarily prepared by an operation of deimimination (deprotection).
- the conventional manufacturing method described above has the following disadvantages. 1) Special flammable substances that are dangerous to handle during bromination Getyl ether is used. 2) It is necessary to prepare multi-step raw material compounds such as protection and deprotection of amino groups.
- An object of the present invention is to provide a simple and efficient operation without using a dangerous solvent such as a special flammable substance in view of the prior art described above.
- An object of the present invention is to provide a method for producing a (3-cyanophenyl) -1-5-( ⁇ [(4-piperidyl) methyl] amino ⁇ methyl) benzoic acid derivative.
- the present inventors have conducted intensive studies in order to achieve the above object, and as a result, have found an efficient production method in which the following reductive amination and protection of the amino group of the piperidine ring are simultaneously performed by a series of operations. This led to the completion of the present invention.
- R is a hydrogen atom, C :!
- To 8 represents an alkyl group, an aryl group, or an aralkyl group.
- the wavy lines may be solid, solid, or a mixture of any ratio thereof to the double bond, and
- R represents a hydrogen atom, a Cl-8 alkyl group, an aryl group, or an aralkyl group.
- the wavy lines may be E-forms, Z-forms, or mixtures of any ratio thereof with respect to the double bond,
- R represents a hydrogen atom, a Cl-8 alkyl group, an aryl group, an aralkyl group, and
- R ′ represents a Cl-8 alkynolecarbonyl group, an arylcarbonyl group, C:!-8 alkoxycarbonyl group, an aryloxycarbonyl group or an aralkoxycarbonyl group.
- R represents a hydrogen atom, a Cl-8 alkyl group, an aryl group, an aralkyl group, and
- R ′ represents a C 1-8 alkylcarbonyl group, an arylcarbonyl group, a C1-8 alkoxycarbonyl group, an aryloxycarbonyl group or an aralkoxycarbonyl group.
- the present invention also provides the following formula (V):
- R represents a C 1-8 alkyl group.
- 3- (3-cyanophenyl) -1-5-formylbenzoic acid derivative and 4- (aminomethyl) piperidine represented by the following formula are dehydrated and condensed in a toluene solution to give the following formula (VI)
- the wavy lines may be in the E-form, the Z-form, or a mixture of any ratio thereof to the double bond, and
- R represents a Cl-8 alkyl group.
- the wavy lines may be E-forms, Z-forms, or mixtures of any ratio thereof with respect to the double bond,
- R represents a Cl-8 alkyl group
- R ′ represents a C 1-8 alkoxycarbonyl group.
- R represents a Cl-8 alkyl group
- R ′ represents a Cl-8 alkoxycarbonyl group.
- the present invention further provides the following formula (V):
- R represents a C 1-8 alkyl group.
- the wavy lines may be in the E-form, the Z-form, or a mixture of any ratio thereof to the double bond, and
- R represents a Cl-8 alkyl group.
- the wavy lines may be E-forms, Z-forms, or mixtures of any ratio thereof with respect to the double bond,
- R represents a Cl-8 alkyl group
- R represents a Cl-8 alkyl group
- R ′ represents a tert-butoxycarbonyl group.
- the present invention provides a novel and useful intermediate obtained by the above-mentioned production method, which has the following formula (II):
- R represents a hydrogen atom, a Cl-8 alkyl group, an aryl group, or an aralkyl group.
- the dehydration condensation (imine formation) from (I) to (11) and (V) to (VI) is performed while removing generated water from the system.
- the solvent to be used include aromatic hydrocarbons such as benzene, toluene and xylene, and among them, toluene is preferable.
- the reaction temperature is not particularly limited, but the reaction is preferably carried out at a relatively high temperature in order to remove generated water from the system, and is preferably from 80 ° C to 150 ° C.
- the reaction time varies depending on the solvent used and the reaction temperature, but is usually 1 hour to 24 hours, preferably 1 hour to 6 hours.
- the protection reaction of the secondary amino group of the pyridyl ring from (II) to (III), (VI) to (VII), and (VI) to (IX) is performed by adding the protective reagent to the reaction solution described above.
- the protective reagent may be added after diluting in a suitable solvent that does not affect the reaction.
- the protecting group is not particularly limited as long as it is used for protecting a general amino group and can withstand a reduction reaction at a later stage.
- the reaction temperature is to suppress side reactions. It is preferable to perform the reaction at a relatively low temperature, usually between 0 ° C and 30 ° C.
- the reduction reaction from (III) to (IV), (VII) to (VIII), and (IX) to (X) is not particularly limited as long as it does not give by-products.
- Metal hydride, electrolysis, etc. can be used.
- the metal hydride used for the reduction includes, for example, a borohydride complex compound, and borane, sodium borohydride, and sodium cyanoborohydride are preferred. Particularly preferred is a nursery.
- the reaction may be performed without concentrating the reaction solution.If necessary, an activator may be added to accelerate the reduction reaction. Is also good.
- the reaction solution containing (IV) thus obtained can be subjected to simple post-treatments such as extraction to obtain high-purity (IV) without complicated purification operations. .
- the present invention provides a novel and useful intermediate obtained by the above-mentioned production method, which is represented by the following formula (III):
- the wavy lines may be E-forms, Z-forms, or mixtures of any ratio thereof with respect to the double bond,
- R represents a hydrogen atom, a Cl-8 alkyl group, an aryl group, an aralkyl group,
- R ' represents a C1-8 alkynolecanoleponyl group, an arylcarbonyl group, a C1-8 alkoxycarbonyl group, a aryloxycarbonyl group or an arylalkoxycarbonyl group.
- C 1-8 alkyl group means a linear or branched C 1-8 alkyl group.
- aryl group examples include a hydrocarbon group aryl group such as a phenyl group and a naphthyl group, and a heteroaryl group such as a pyridyl group and a furyl group, and preferably a phenyl group. It is.
- the “aralkyl group” specifically includes a benzyl group, a phenethyl group, a phenylpropyl group, a 1-naphthylmethyl group, a 2-naphthylmethyl group and the like, and preferably a benzyl group.
- the alkyl group of the “C 1-8 alkylcarbonyl group” means a linear or branched carbon chain having 1 to 8 carbon atoms, specifically, a methyl group, an ethyl group, Propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentinole, neopentyl, isopentyl, 1,2-dimethylpropyl, hexyl , Isohexyl, 1, 1-dimethylbutyl, 2, 2-dimethynolebutyl, 1-ethynolebutyl, 2-ethynolebutyl, iso Examples thereof include a heptyl group, an octyl group, and an isooctyl group, and preferably have 1 to 4 carbon atoms, and particularly preferably a methyl group and an ethyl group.
- aryl group of the “aryl carbonyl group” include a hydrocarbon group aryl group such as a phenyl group and a naphthyl group, and a heteroaryl group such as a pyridyl group and a furyl group. And preferably a phenyl group.
- C 1-8 alkoxycarbonyl alkoxy group
- a methoxy group an ethoxy group, a propoxy group, an isopropoxy group, a butoxy group, an isobutoxy group and a sec-butoxy group.
- aryl group of the “aryloxycarbonyl group” include a hydrocarbon ring aryl group such as a phenyl group and a naphthyl group, a pyridyl group, a furyl group, and the like. And a heteroaryl group, and preferably a phenyl group.
- aralkoxy group of the “aralkoxycarbonyl group” include a benzyloxy group, a phenetinoleoxy group, a pheninolepropyloxy group, a 1-naphthyl.methyloxy group, and a 2-naphthylmethyloxy group. And the like, and preferably a benzyloxy group.
- the wavy line in the formula of the present invention indicates the E-form, Z It can be the body, or a mixture thereof.
- 3- (3-cyanophenyl) _ is a useful intermediate for producing a biphenylamidine derivative which is an anticoagulant having an excellent FXa inhibitory action described in WO099 / 26918.
- 5 _ ( ⁇ [(4-Piperidyl) methyl] amino ⁇ methyl)
- Benzoic acid derivative can be produced simply and efficiently without using dangerous organic solvents which may cause ignition.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hydrogenated Pyridines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002559393A JPWO2002059091A1 (ja) | 2001-01-26 | 2002-01-22 | シアノフェニル安息香酸誘導体の製造法 |
EP02734832A EP1361213A4 (en) | 2001-01-26 | 2002-01-22 | METHOD FOR THE PRODUCTION OF CYANOPHENYLBENEOIC ACID DERIVATIVES |
US10/470,378 US20040072866A1 (en) | 2001-01-26 | 2002-01-22 | Process for preparation of cyanophenylbenzoic acid derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001-18224 | 2001-01-26 | ||
JP2001018224 | 2001-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002059091A1 true WO2002059091A1 (fr) | 2002-08-01 |
Family
ID=18884278
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/000437 WO2002059091A1 (fr) | 2001-01-26 | 2002-01-22 | Procede de preparation de derives d'acide cyanophenylbenzoique |
Country Status (5)
Country | Link |
---|---|
US (1) | US20040072866A1 (ja) |
EP (1) | EP1361213A4 (ja) |
JP (1) | JPWO2002059091A1 (ja) |
CN (1) | CN1610665A (ja) |
WO (1) | WO2002059091A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6538137B1 (en) * | 1999-05-17 | 2003-03-25 | Teijin Limited | Cyanobiphenyl derivatives |
CN106973857A (zh) * | 2017-04-16 | 2017-07-25 | 贵州黔东南桥水农业科技开发有限责任公司 | 一种繁殖野生棘腹蛙的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11152269A (ja) * | 1997-11-20 | 1999-06-08 | Teijin Ltd | ビフェニルアミジン誘導体 |
EP1043310A1 (en) * | 1997-11-20 | 2000-10-11 | Teijin Limited | Biphenylamidine derivatives |
WO2000069811A1 (fr) * | 1999-05-17 | 2000-11-23 | Teijin Limited | Derives de cyanobiphenyle |
-
2002
- 2002-01-22 CN CNA028069757A patent/CN1610665A/zh active Pending
- 2002-01-22 EP EP02734832A patent/EP1361213A4/en not_active Withdrawn
- 2002-01-22 US US10/470,378 patent/US20040072866A1/en not_active Abandoned
- 2002-01-22 JP JP2002559393A patent/JPWO2002059091A1/ja not_active Withdrawn
- 2002-01-22 WO PCT/JP2002/000437 patent/WO2002059091A1/ja not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11152269A (ja) * | 1997-11-20 | 1999-06-08 | Teijin Ltd | ビフェニルアミジン誘導体 |
EP1043310A1 (en) * | 1997-11-20 | 2000-10-11 | Teijin Limited | Biphenylamidine derivatives |
WO2000069811A1 (fr) * | 1999-05-17 | 2000-11-23 | Teijin Limited | Derives de cyanobiphenyle |
Non-Patent Citations (1)
Title |
---|
See also references of EP1361213A4 * |
Also Published As
Publication number | Publication date |
---|---|
CN1610665A (zh) | 2005-04-27 |
JPWO2002059091A1 (ja) | 2004-05-27 |
EP1361213A4 (en) | 2004-06-09 |
EP1361213A1 (en) | 2003-11-12 |
US20040072866A1 (en) | 2004-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI329106B (en) | Process for the manufacture of organic compounds | |
CA2564223A1 (fr) | Procede de preparation de derives n-piperidino-1,5-diphenylpyrazole-3-carboxamide | |
CN1216868C (zh) | 吡啶-1-氧化物衍生物及其转化为药物活性化合物的方法 | |
WO2004009553A1 (ja) | 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法 | |
JPS6036436B2 (ja) | 10‐〔ω‐(ベンゾイルピペリジニル)アルキル〕フエノチアジアジンおよびその酸付加塩ならびにそれらの製造法 | |
WO2002059091A1 (fr) | Procede de preparation de derives d'acide cyanophenylbenzoique | |
CA2098241A1 (en) | Tetrazolyl-(phenoxy and phenoxyalkyl)-piperidinylpyridazines as antiviral agents | |
CZ330697A3 (cs) | Způsob výroby recemického a enanciomerního 1-(pyridyl)-2-cyklohexylethylaminu | |
JP4031366B2 (ja) | アムロジピンの製造方法 | |
KR101686087B1 (ko) | 광학 활성을 갖는 인돌린 유도체 또는 이의 염의 신규 제조 방법 | |
RU2264391C2 (ru) | Способ получения производного хинолинкарбоксальдегида и промежуточных соединений | |
EP1357108A1 (en) | Benzamidine derivatives and process for production thereof | |
CN113214142B (zh) | 一种阿哌沙班的中间体及制备方法 | |
KR101605185B1 (ko) | 2-(2-프탈이미도에톡시)아세트산의 제조방법 | |
AU2023206696A1 (en) | Method for preparing pyrrole compound and intermediate thereof | |
JP4389548B2 (ja) | フルオレン骨格を有するアリールアミン誘導体と芳香族炭化水素との包接化合物、及びアリールアミン誘導体の分離精製方法。 | |
JP4441260B2 (ja) | 4−アミノ−4−フェニルピペリジン類の製造方法 | |
JPH0649681B2 (ja) | 3‐シアノ‐4‐アリールピロールの製造法 | |
WO2002076958A1 (fr) | Procede de production de composes oxazoles 5-substitues et de composes imidazoles 5-substitues | |
JP3202120B2 (ja) | 1,4−ジヒドロピリジン誘導体及びそれを用いる1,4−ジヒドロピリジンカルボン酸誘導体の製造方法 | |
JP4287083B2 (ja) | 2−または4−モノ置換ピリジンの製造方法並びに4−モノ置換ピリジンまたはその塩の選択的製造方法および分離方法 | |
EP0950052B1 (fr) | Procede pour la preparation d'un derive de tetrahydropyridine | |
JP4032593B2 (ja) | 4−アミノテトラヒドロピラン誘導体の製法 | |
JP4869537B2 (ja) | テトラヒドロピラン−4−オールの製法 | |
JP5902671B2 (ja) | ベンジルピラゾール誘導体の製造方法およびその製造中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002559393 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002734832 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10470378 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 028069757 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002734832 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002734832 Country of ref document: EP |